109 related articles for article (PubMed ID: 20309941)
1. Effects of tyroservatide on histone acetylation in lung carcinoma cells.
Xu Q; Lu R; Zhu ZF; Lv JQ; Wang LJ; Zhang W; Hu JW; Meng J; Lin G; Yao Z
Int J Cancer; 2011 Jan; 128(2):460-72. PubMed ID: 20309941
[TBL] [Abstract][Full Text] [Related]
2. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV).
Zhu Z; Jia J; Lu R; Lu Y; Fu Z; Zhao L; Wang L; Jin M; Zhao L; Gao W; Yao Z
Int J Cancer; 2006 Mar; 118(6):1539-44. PubMed ID: 16184552
[TBL] [Abstract][Full Text] [Related]
3. [Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines].
Chen YX; Fang JY; Lu J; Qiu DK
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):312-7. PubMed ID: 15059516
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
7. Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Kang KA; Piao MJ; Kim KC; Zheng J; Yao CW; Cha JW; Kim HS; Kim DH; Bae SC; Hyun JW
Int J Oncol; 2013 Dec; 43(6):1907-14. PubMed ID: 24100442
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
9. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
11. Tyroservatide therapy for tumor growth, invasion and metastasis of Lewis lung carcinoma and human lung carcinoma A549.
Zheng M; Lu R; Che X; Li J; Zhou C; Wang L; Xu Q; Cao H; Li Q; Yao Z
Oncology; 2006; 70(6):418-26. PubMed ID: 17245103
[TBL] [Abstract][Full Text] [Related]
12. L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.
Huang H; Liu N; Guo H; Liao S; Li X; Yang C; Liu S; Song W; Liu C; Guan L; Li B; Xu L; Zhang C; Wang X; Dou QP; Liu J
PLoS One; 2012; 7(11):e49062. PubMed ID: 23139833
[TBL] [Abstract][Full Text] [Related]
13. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M
J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
[TBL] [Abstract][Full Text] [Related]
14. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.
Oya Y; Mondal A; Rawangkan A; Umsumarng S; Iida K; Watanabe T; Kanno M; Suzuki K; Li Z; Kagechika H; Shudo K; Fujiki H; Suganuma M
J Nutr Biochem; 2017 Apr; 42():7-16. PubMed ID: 28103535
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.
Sambucetti LC; Fischer DD; Zabludoff S; Kwon PO; Chamberlin H; Trogani N; Xu H; Cohen D
J Biol Chem; 1999 Dec; 274(49):34940-7. PubMed ID: 10574969
[TBL] [Abstract][Full Text] [Related]
17. [Effect of curcumin on acetylation of histone H3 in human lymphoma cell line Raji].
Li XG; Chen Y; Wu Q; Sun CY
Ai Zheng; 2006 May; 25(5):582-6. PubMed ID: 16687078
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
Long J; Zhao J; Yan Z; Liu Z; Wang N
Int J Cancer; 2009 Mar; 124(5):1235-44. PubMed ID: 19058176
[TBL] [Abstract][Full Text] [Related]
19. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
20. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
